Discovery of putative breast cancer antigens using an integrative platform of genomics‐driven immunoproteomics
Authors:
- 30 June 2017
- journal article
- research article
- Published by Wiley in Proteomics
- Vol. 17 (15-16) , 1600318
Abstract
Recent advances in cancer immuno‐therapeutics such as checkpoint inhibitors, chimeric antigen‐receptor T cells, and tumor infiltrating T cells (TIL) are now significantly impacting cancer patients in a positive manner. Although very promising, reports indicate no more than 25% of cases result in complete remission. One of the limitations of these treatments is the identity of putative cancer antigens in each patient, as it is technically challenging to identify cancer antigens in a rapid fashion. Thus, identification of cancer antigens followed by targeted treatment will increase the efficacy of cancer immunotherapies. To achieve this goal, a combined technologies platform of deep genomic sequencing and personalized immune assessment was devised, termed Genomics Driven Immunoproteomics (GDI). Using this technological platform, we report the discovery of 149 tumor antigens from human breast cancer patients. Significant number of these putative cancer antigens arise from single nucleotide variants (SNVs), as well as insertions and deletions that results into frame‐shift mutations. We propose a general model of anti‐cancer immunity and suggest that the GDI platform may help identify patient‐specific tumor antigens in a timely fashion for precision immunotherapies.Keywords
Funding Information
- CT Stem Cell Established Investigator
This publication has 42 references indexed in Scilit:
- Adoptive cell transfer as personalized immunotherapy for human cancerScience, 2015
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- The Dizzying Journey to a New Cancer ArsenalScience, 2013
- Cancer Genome LandscapesScience, 2013
- Immunology beats cancer: a blueprint for successful translationNature Immunology, 2012
- T-cell therapy at the thresholdNature Biotechnology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Whole genome sequencing for quantifying germline mutation frequency in humans and model species: Cautious optimismMutation Research - Reviews in Mutation Research, 2012
- Immune Therapy Steps Up the AttackScience, 2010
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996